Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess a priori what the models need to represent.

That was the conclusion of an FDA workshop convened with the American Association for Cancer Research (AACR) in the wake of treatment-related deaths last year in clinical trials of Merck & Co. Inc.’s anti-PD-1 mAb Keytruda pembrolizumab...